Investigational drug · Phase 2
NAs
Also called: Nucleoside analogs, acid
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis B, HBV Infection With LLV.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
96
Any phase or sponsor naming "NAs"
First trial start
2024
Nov 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NAs", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B
- HBV Infection With LLV
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "NAs" as an intervention, largest first.
Huashan HospitalAcademic, hospital or other
NCT04896255 · 33,000 participants (planned) · Start Sep 9, 2020 · Primary completion Nov 1, 2026
Drug: peginterferon alpha based regimen; nucleos(t)ide · For: Chronic Hepatitis b
Sites: Shanghai, China
- A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon AlphaNot yet recruiting
xieqingAcademic, hospital or other
NCT07537387 · 10,000 participants (planned) · Start Apr 30, 2026 · Primary completion Dec 31, 2029
Drug: PEG IFNα-2b monotherapy or combination therapy with NAs; NAs monotherapy group · For: Chronic Hepatitis b
Sites: Shanghai, China
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05182463 · 5,000 participants (planned) · Start Jan 8, 2022 · Primary completion Dec 13, 2026
Drug: Peginterferon Alfa-2B; Nucleoside Analogs · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- Study on Screening, Verification and Intervention of High-risk Patients With Liver CancerPivotal-lookingStatus unknown
Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
NCT05721300 · 2,215 participants (planned) · Start Feb 10, 2023 · Primary completion Dec 31, 2024
Drug: NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combined with interferon treatments; NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatments · For: Hepatocellular Carcinoma; Chronic Hepatitis B
Sites: Xiamen, China
Qing XIeAcademic, hospital or other
NCT06323681 · 2,016 participants (planned) · Start Feb 4, 2024 · Primary completion Feb 2027
Drug: Peginterferon α-2b based treatment group; NAs monotherapy group · For: Chronic Hepatitis b
Sites: Shanghai, China
- Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)Pivotal-lookingRecruiting
Humanity & Health Medical Group LimitedAcademic, hospital or other
NCT03792919 · 2,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Stop current treatment (anti-HBV neucleos(t)ides); Keep current treatment (anti-HBV neucleos(t)ides) · For: Chronic Hepatitis B
Sites: Hong Kong, Hong Kong
Beijing 302 HospitalAcademic, hospital or other
NCT06926647 · 2,000 participants (planned) · Start May 1, 2025 · Primary completion Dec 15, 2028
Drug: Nucleos(t)ide Analogues; Interferon alfa and 1 more · For: HBV; Chronic Hepatitis b
Sites: Ankang, China; Anyang, China; Beihai, China · 85 sites in all
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06368882 · 1,500 participants (planned) · Start Jan 1, 2024 · Primary completion Dec 31, 2028
Drug: Peg-Interferon α · For: Nonalcoholic Fatty Liver Disease; Chronic Hepatitis b
Sites: Ningbo, China; Rui’an, China; Wenzhou, China · 5 sites in all
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT07079150 · 1,500 participants (planned) · Start Jan 1, 2025 · Primary completion Jan 2032
Drug: Peg IFN-α-2b · For: Hepatitis B, Chronic (CHB); Hepatitis B; Hepatitis B Virus (HBV)
Sites: Xi'an, China · 2 sites in all
- A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHBPivotal-lookingNot yet recruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07095855 · 1,300 participants (planned) · Start Aug 2025 · Primary completion Jan 2028
Drug: ZM-H1505R 100mg · For: Chronic Hepatitis B
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- Gut microbiota and metabolic characteristics in PWHIV with metabolic dysfunction-associated steatotic liver disease (MASLD).
Liu H, Xu T, Guo Y, et al. · Virulence 2027
- 2022 WHO estimates for overall and human papillomavirus test-based cervical cancer screening coverage worldwide: a review and synthetic analysis.
Serrano B, Roura E, Alemany L, et al. · Lancet Glob Health 2027
- Integrated metabolic and process engineering of Rhodotorula toruloides for light-driven hydrocarbon production.
Zhao H, Zhang Y, Lyu L, et al. · Synth Syst Biotechnol 2027
- Systematic metabolic engineering for trans-aconitic acid production in Aspergillus niger.
Wang S, He J, Li W, et al. · Synth Syst Biotechnol 2027
- Screening a thermotolerant Komagataella phaffii strain with methanol cross-tolerance and the associated physiological and transcriptional responses.
Li C, Jiang T, Bo Y, et al. · Synth Syst Biotechnol 2027
- A pseudo-labeling approach for automated assignment of unlabeled proteins exceeding 100 amino acid residues.
Niu X, Hou X, Jin C · Magn Reson Lett 2027
Also in development for Chronic Hepatitis B
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.